EN DE
Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation

Pharmaniaga Bhd (7081) fair value: what the stock is really worth

As of Sep 23, 2026: fair value of Pharmaniaga Bhd MYR 0.69, price MYR 1.08, upside -36.3%, quality 29 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

  1. Fair value above price? No
  2. Good quality? No
  3. Add to watchlist

Healthcare · MY · ISIN MYL7081OO002

PB Thin data Sep 23, 2026

Pharmaniaga Bhd

7081 · KLSE

Weakest SetupStrongly overvalued and low quality.

!Fair value 0.6885 MYR · Strongly overvalued (−36%)
!Quality 29/100
!Expensive Growth (revenue 5y +7.6 %/yr)
!Thin margins · 1.2% net margin (TTM)
!Low debt · negative free cash flow
·1.20% dividend yield
!Trails peers (4/13)
!Narrow moat 44/100
!Evidence only low, so the estimate is less certain
!Weak on dividend: 24 out of 100
Watch Pharmaniaga Bhd for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card. Watch for free Pro now: $1 first month

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

3.36 MYR 0.5894 MYR Fair Value 0.6885 MYR Apr 2021 Sep 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 23, 2026.

How to read this chart

60‑month range 0.5894 MYR – 3.36 MYR · fair‑value band 0.5185 MYR – 0.8670 MYR · the 1.08 MYR price screens above the 0.6885 MYR fair value. Dashed = 300-day average. As of Sep 23, 2026.

Follow Pharmaniaga Bhd in your weekly email

Every Wednesday you see whether Pharmaniaga Bhd is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Pharmaniaga Berhad, an investment holding company, operates as an integrated healthcare service provider in Malaysia, Indonesia, and internationally. The company operates through Logistics and Distribution, Manufacturing, and Indonesia segments.

Show more

Pharmaniaga Berhad, an investment holding company, operates as an integrated healthcare service provider in Malaysia, Indonesia, and internationally. The company operates through Logistics and Distribution, Manufacturing, and Indonesia segments. It is involved in manufacturing, distribution, and marketing of pharmaceutical and medical products, such as generic drugs and over-the-counter medicines; supply and installation of medical and hospital equipment; and research and development of pharmaceutical products. The company also produces and distributes food supplements. In addition, it distributes and trades diagnostic products; and develops OLIN digital platform, an integrated digital platform for ordering, inventory, billing, and sales operations. Further, the company provides logistics services and primary care products for acute diseases and specialty care products for serious and chronic diseases. Pharmaniaga Berhad was founded in 1994 and is based in Shah Alam, Malaysia.

Stock analysis

Pharmaniaga Bhd (7081) currently trades at 1.08 MYR, while our model-based Fair Value estimate is 0.6885 MYR, implying the stock looks roughly 56.9% overvalued today.

Show more

Valuation

Bull case: the DCF Models group reads highest at a median of 1.08 MYR per share, and 3 of the 15 models we run sit above the 1.08 MYR price.

Bear case: the Asset-Based group reads lowest at 0.2200 MYR, and 12 of the 15 models stay below the price. Evidence for this calculation is low.

Scenario range: 0.5185 MYR (bear) to 0.8670 MYR (bull), the price of 1.08 MYR sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 29/100 (below-average quality), in the Healthcare sector.

Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.

Pharmaniaga Bhd reported revenue of 3.9B MYR in FY2025 versus 4.8B MYR in FY2021, a compound −5.0%/yr. Reported net income was 48.5M MYR in FY2025, compounding −27.1%/yr from FY2021.

Key figures

Market cap 1.6B MYR (≈ $396M) · P/E ratio 36.0 · P/S ratio 0.44 · EPS (TTM) 0.0300 MYR · Dividend yield 1.2% · Net margin 1.2% · Return on equity 28.4% · Return on assets (EBIT) 1.1%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 38 out of 100 (low confidence).

What moves the price

The share trades about 33% below its 52-week high and at its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at 35% fair-value upside, at −36%, 7081 screens richer than that median.

Fair Value models

Bear 0.5185 MYR Fair Value 0.6885 MYR Bull 0.8670 MYR
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2025 figures (about 9 months old). Earnings retained since then (0.0125 MYR per share) are deliberately not added. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
Owner Earnings 0.7500 MYR 1.08 MYR 1.52 MYR 77
Residual Income 0.2800 MYR 0.3100 MYR 0.4400 MYR 76
EPV 0.6300 MYR 0.7200 MYR 0.7900 MYR 74
All 15 models by family
DCF Models
Owner Earnings 0.7500 MYR 1.08 MYR 1.52 MYR 77
Earnings-Based
Graham-Dodd 0.2500 MYR 0.7500 MYR 1.00 MYR 65
Lynch FV 0.1600 MYR 0.2300 MYR 0.3000 MYR 61
PEG = 1.0 0.1600 MYR 0.2300 MYR 0.3000 MYR 57
EPV 0.6300 MYR 0.7200 MYR 0.7900 MYR 74
Multiples
P/E Multiple 0.6100 MYR 0.8100 MYR 1.02 MYR 63
P/S Multiple 0.4700 MYR 0.6300 MYR 0.7900 MYR 58
P/B Multiple 0.4700 MYR 0.6300 MYR 0.7900 MYR 55
EV/EBIT 1.25 MYR 1.67 MYR 2.09 MYR 66
EV/EBITDA 1.34 MYR 1.79 MYR 2.24 MYR 67
EV/Revenue 0.8900 MYR 1.27 MYR 1.66 MYR 53
Asset-Based
NCAV (Graham) 0.1700 MYR 0.2200 MYR 0.3300 MYR 54
Economic Profit
Residual Income 0.2800 MYR 0.3100 MYR 0.4400 MYR 76
ROIC Compounder 0.6700 MYR 0.8100 MYR 0.9600 MYR 72
Growth Earnings
Growth-Adj P/E 0.5000 MYR 0.7100 MYR 0.9200 MYR 67

Open the full fair value analysis →

Notify me when 7081 reaches fair value

Put 7081 on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 29/100

Of which business quality 28 · Market factors (momentum, volatility) 31

Profitability 45
Margins and returns on capital today
Quality Growth 13
Are margins and returns improving?
Cashflow 13
Earnings quality: real cash, not paper profit
Fin. Strength 25
Balance sheet, leverage, solvency risk
Investment 83
Disciplined investing over empire-building
Low Volatility 52
Calm price path (market factor)
Momentum 28
Price trend over the last 3–12 months (market factor)
52W Momentum 11
Distance to the 52-week high (market factor)
Net Issuance 0
Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 48/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+4.5%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+4.1%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+7.6%
Start year 2020 (pandemic). Over 10 years: +6.0% a year
Revenue growth 13 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+6.1%
What shareholders gained per year (last 5 years), in MYR ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Measured in MYR: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
−1.3%
Earnings growth per share plus dividend.
Earnings per share, growth per year−2.5%
Dividend (yield on the price)1.2%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.−3% vs 7%, slowing
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.3% → 3%
Start year 2020 (pandemic)

7081 screens 57% overvalued. Compare with McKesson Corporation →

Compare Pharmaniaga Bhd with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Distribution · 83 stocks

Beats the industry median on 4/13 measures
Overall it trails its industry peers.
Valuation
Quality Score 29 · Bottom 25%
Fair Value upside −36% · Bottom 25%
Profitability
Return on equity (TTM) 28% · Top 25%
Return on assets 3% · Above median
Net margin (TTM) 1% · Below median
Operating margin (TTM) 5% · Above median
Growth and dividend
Revenue growth 12% · Top 25%
Dividend yield (TTM) 1.2% · Below median
Balance sheet
Debt / equity 0.29× · Above median

Valuation Multiplesvs Medical Distribution median · lower = cheaper

P/E (TTM) 36.0× · Priciest 25%
P/B 3.71× · Priciest 25%
P/S (TTM) 0.40× · Pricier than median
EV/EBITDA 11.0× · Pricier than median

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 42
FUTURE (revenue growth)59 · sector 17
PAST (return on equity)100 · sector 27
HEALTH (low debt)86 · sector 96
DIVIDEND (yield)24 · sector 59

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Medical Distribution stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value
McKesson Corporation MCK $891.23 $819.31 −8%
Cencora, Inc COR $314.43 $211.07 −33%
Cardinal Health, Inc CAH $222.04 $141.77 −36%
Henry Schein, Inc HSIC $87.43 $76.86 −12%
Shanghai Pharmaceuticals Holding 601607 ¥16.06 ¥42.67 +166%
Sinopharm Group 1099 HK$15.06 HK$58.89 +291%
Galenica AG GALE CHF 83.45 CHF 61.79 −26%
Guangzhou Baiyunshan Pharmaceutical Holdings 600332 ¥19.67 ¥26.64 +35%
Jointown Pharmaceutical Group 600998 ¥4.89 ¥9.84 +101%
China National Medicines Corporation 600511 ¥26.11 ¥58.47 +124%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
DCF CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorFama-French ModelIntrinsic Value
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Pharmaniaga Bhd · Fair Value
0.6885 MYR −57%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "Pharmaniaga Bhd Fair Value". https://www.fairvalue-calculator.com/stock/7081

Frequently asked questions

Is Pharmaniaga Bhd (7081) overvalued or undervalued?
As of Sep 23, 2026, our model estimates a fair value of 0.6885 MYR versus a price of 1.08 MYR, about −36% upside (overvalued).
What is the fair value of 7081?
Our model-based fair value for Pharmaniaga Bhd is 0.6885 MYR (as of Sep 23, 2026), built from audited fundamentals. The current price: 1.08 MYR.
What is the quality score of 7081?
Pharmaniaga Bhd has a Quality Score of 29/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Pharmaniaga Bhd (7081)?
Our model-based price target is the fair value of 0.6885 MYR (as of Sep 23, 2026) from 15 valuation models. Cautious scenario 0.5185 MYR, optimistic scenario 0.8670 MYR. It is a calculation from audited fundamentals, not an analyst target.
What is the Pharmaniaga Bhd stock forecast for 2026?
Our models put fair value at 0.6885 MYR, about −36% upside versus a price of 1.08 MYR (overvalued). Cautious scenario 0.5185 MYR, optimistic scenario 0.8670 MYR. The calculation is refreshed regularly with new filings.
What is the revenue of Pharmaniaga Bhd (7081)?
Pharmaniaga Bhd reported trailing-twelve-month revenue of about 4.1B MYR (latest available figure, as of Sep 23, 2026).
Does Pharmaniaga Bhd pay a dividend?
Pharmaniaga Bhd currently shows a dividend yield of about 1.20% relative to its recent price (as of Sep 23, 2026).
What is the intrinsic value of Pharmaniaga Bhd (7081)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Pharmaniaga Bhd it is 0.6885 MYR per share (as of Sep 23, 2026), against a price of 1.08 MYR. It is the blended result of 15 valuation models (cash flow, earnings, asset, dividend).
Is Pharmaniaga Bhd stock overvalued or undervalued in 2026?
As of Sep 23, 2026, 7081 trades above its calculated fair value: price 1.08 MYR, fair value 0.6885 MYR, a gap of about −36% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 7081?
No. The price is what the market pays today (1.08 MYR); the fair value is what the company's own numbers justify (0.6885 MYR). For Pharmaniaga Bhd the two are 0.3915 MYR per share apart. That gap is exactly why we show both numbers side by side.
How much is Pharmaniaga Bhd worth?
The market values Pharmaniaga Bhd at about 1.6B MYR (market capitalisation, as of Sep 23, 2026). Per share that is 1.08 MYR; our models calculate a fair value of 0.6885 MYR per share.
What do the bullish and bearish scenarios say about 7081?
Our models span a range for Pharmaniaga Bhd: cautious scenario 0.5185 MYR, base 0.6885 MYR, optimistic 0.8670 MYR per share (as of Sep 23, 2026, price 1.08 MYR). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 7081?
Pharmaniaga Bhd trades at a price-to-earnings ratio of 36.0 (as of Sep 23, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of 0.6885 MYR is built from several models across several years. Other multiples: P/B 3.7, P/S 0.4, EV/EBITDA 11.0.
How solid is the balance sheet of Pharmaniaga Bhd (7081)?
Balance-sheet figures for Pharmaniaga Bhd (as of Sep 23, 2026): return on equity 28.4%, debt of 0.29 per unit of equity. They feed the Quality Score of 29/100, which measures business quality independently of the share price.
How far is 7081 from its 52-week high?
Pharmaniaga Bhd trades at 1.08 MYR, about 33% below its 52-week high of 1.61 MYR and at the low of 1.08 MYR (as of Sep 23, 2026). Distance from the high says nothing about value: that is what the fair value of 0.6885 MYR is for.
Which stocks are comparable to Pharmaniaga Bhd?
From the same area (Healthcare) we also value McKesson Corporation, Cencora, Inc, Cardinal Health, Inc, Henry Schein, Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Pharmaniaga Bhd stock attractive at the current price?
The data as of Sep 23, 2026: price 1.08 MYR, calculated fair value 0.6885 MYR (−36%), Quality Score 29/100, from 15 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 7081 calculated?
We run Pharmaniaga Bhd through 15 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of 0.6885 MYR, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.1 % above its aggregate fair value. Pharmaniaga Bhd itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Pharmaniaga Bhd (7081)?
The closing price on Sep 23, 2026 was 1.08 MYR. Our model-based fair value is 0.6885 MYR, about −36% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Pharmaniaga Bhd right now?
The price sits above even our optimistic bull case (0.8670 MYR). The favourable scenario is already priced in. Weak quality (29/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.

Key figures of Pharmaniaga Bhd

How large is the market capitalisation of Pharmaniaga Bhd (7081)?
The market capitalisation of Pharmaniaga Bhd is 1.6B MYR (≈ $396M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Pharmaniaga Bhd (7081)?
The price-to-sales ratio of Pharmaniaga Bhd is 0.44 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Pharmaniaga Bhd (7081)?
Earnings per share at Pharmaniaga Bhd are 0.0300 MYR (price ÷ EPS = P/E 36.0). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Pharmaniaga Bhd (7081)?
The dividend yield of Pharmaniaga Bhd is 1.2% (payout 43.3%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Pharmaniaga Bhd (7081)?
The net margin of Pharmaniaga Bhd is 1.2% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Pharmaniaga Bhd (7081)?
The return on equity (ROE) of Pharmaniaga Bhd is 28.4% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Pharmaniaga Bhd (7081)?
On an EBIT basis the return on assets of Pharmaniaga Bhd is 1.1% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Pharmaniaga Bhd (7081)?
The operating margin of Pharmaniaga Bhd is 4.7% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Pharmaniaga Bhd (7081)?
Revenue at Pharmaniaga Bhd is growing +11.7% versus a year earlier (3y avg +4.1%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Pharmaniaga Bhd (7081)?
Earnings per share at Pharmaniaga Bhd are growing −76.6% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Pharmaniaga Bhd (7081) generate?
The free cash flow of Pharmaniaga Bhd is −47.5M MYR (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Pharmaniaga Bhd (7081) carry?
The net debt of Pharmaniaga Bhd is 709M MYR (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch Pharmaniaga Bhd in the live analysis

One click puts Pharmaniaga Bhd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.